The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Inducing and exploiting vulnerabilities for the treatment of liver cancer
Open accessAbstract
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies 1,2; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma 3. The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis)4,5. Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition 6 is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescence induction by inhibition of DNA replication kinase CDC7 has also been paired with a senolytic that disrupts mTOR signaling, inducing apoptosis in senescent human liver cancer cells and improving survival in mouse models of HCC (Wang et al. 2019).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Wang et al. 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, many of the genes have been denoted as possible therapeutic targets in a variety of epithelial-based cancers, such as CDC7 in oral squamous carcinoma30 and liver cancer31, ATP1B3 in gastric cancer32, and FKBP14 in ovarian cancer33.”
From Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature (2023) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“In a mouse model of liver cancer, the mTOR inhibitor AZD8055 also showed senolytic potential against cancer cells with senescence induced by small- molecule inhibitors of CDC7 (ref. 207 ) .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [207]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Elevated expression of p16 in melanocytes156 and epidermal and dermal cells157,158 is associated with human aging.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [156]
Experimental — accuracy not yet measuredIn the citing paper
“Based on the preclinical experimental evidence enumerated here, approaches based on the induction of senescence in large fraction of tumors have the potential to enter the realm of the clinical practice, even more if combined with adjuvant immunotherapy or senolytic therapy to remove potentially harmful senescent escaper variants, as recently proposed.189,202,203”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [202]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Self-citationThe comet assay: a method to measure DNA damage in individual cells
Olive, P. L., & Banáth, J. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.5 · Cited by 1,845
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Cited by
Sorted by citations
Items 401–432 of 432
Zhuang, H., Zhang, Z., Chen, B., Tang, C., Chen, X., Tan, W., Yang, L., Xie, Z., Ma, X., Wang, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590802
Zhuang, H., Zhang, Z., Chen, B., Tang, C., Chen, X., Tan, W., Yang, L., Xie, Z., Ma, X., Wang, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590799
Liu, L., Wang, Q., Wu, L., Zhang, L., Huang, Y., Yang, H., guo, L., Fang, Z., & Wang, X. (2023) · Figshare · doi:10.6084/m9.figshare.23689659
Chen, Y., Li, L., Lan, J., Cui, Y., Rao, X., Zhao, J., Xing, T., Ju, G., Song, G., Lou, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.17869906
Liu, L., Wang, Q., Wu, L., Zhang, L., Huang, Y., Yang, H., guo, L., Fang, Z., & Wang, X. (2023) · Figshare · doi:10.6084/m9.figshare.23689650
Liu, L., Wang, Q., Wu, L., Zhang, L., Huang, Y., Yang, H., guo, L., Fang, Z., & Wang, X. (2023) · Figshare · doi:10.6084/m9.figshare.23689662
Liu, L., Wang, Q., Wu, L., Zhang, L., Huang, Y., Yang, H., guo, L., Fang, Z., & Wang, X. (2023) · Figshare · doi:10.6084/m9.figshare.23689656
Guo, Y., Wang, J., Benedict, B., Yang, C., van Gemert, F., Ma, X., Gao, D., Wang, H., Zhang, S., Lieftink, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16829572
Self-citationZhuang, H., Zhang, Z., Chen, B., Tang, C., Chen, X., Tan, W., Yang, L., Xie, Z., Ma, X., Wang, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590796
Hao, W., Chen, Z., Tang, J., Ru, Y., Gao, W., & Xu, H. (2024) · Figshare · doi:10.6084/m9.figshare.26646070
Xue, M., Dong, L., Zhang, H., Li, Y., Qiu, K., Zhao, Z., Gao, M., Han, L., Chan, A., Li, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25132035
Zhuang, H., Zhang, Z., Chen, B., Tang, C., Chen, X., Tan, W., Yang, L., Xie, Z., Ma, X., Wang, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590793
Guo, Y., Wang, J., Benedict, B., Yang, C., van Gemert, F., Ma, X., Gao, D., Wang, H., Zhang, S., Lieftink, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16829566
Self-citationSenolytic Changes in Murine Arteriovenous Fistulas with CKD
Kane, J., Kilari, S., Lemieux, A., Singh, P. G., Anderson, N., Saul, D., Tchkonia, T., Kirkland, J. L., & Misra, S. (2026) · Kidney360 · doi:10.34067/kid.0000001104
Liang, L., Liu, S., Li, Y., Zeng, F., He, Q., Wang, Z., Deng, J., & Zhou, Y. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02848-6 · Cited by 1
Zhang, X., Yang, L., He, X., Zhao, M., Fang, Z., Xu, G., Duan, Z., & Luo, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.03.050
Senolytic drug discovery and mechanisms of action in BRAF-V600E oncogene-induced senescence
L’Hôte, V. (2022) · theses.fr (ABES) · doi:10.70675/acd5f426zc1b2z446fz8404z0f8f121081f8
Influence of centrosome amplification on the response to chemotherapy in epithelial ovarian cancer
Fantozzi, G. (2023) · theses.fr (ABES) · doi:10.70675/9023fab1z003az407bz9b02z2054939e787d
Identification of Combinatorial Targets for Anticancer Drug Discovery
Huang, M., & Geng, M. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0011
Blue period - features of senescence 30 years after beta-galactosidase
Kuehnemann, C., & Wiley, C. D. (2026) · Aging · doi:10.18632/aging.206380
Deep Feature Learning for Liver Tumor DiagnosisPreprint
Al-alas, M., Lin, W. Y., Alghaili, M., Alkhasheb, H. M. A., & Jie, W. (2026) · Research Square · doi:10.21203/rs.3.rs-9466362/v1
Galanti, L., & Pfander, B. (2026) · Communications Biology · doi:10.1038/s42003-026-10512-5
Han, Y., Ma, L., & Ma, X. (2026) · Biology Direct · doi:10.1186/s13062-026-00908-y
Wang, R., Shang, D., Tu, Z., & Liu, H. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2709798
Shen, Y., He, L., Zheng, C., Liu, D., He, Z., Zou, Y., Wu, G.-S., He, C., Wang, X., Ding, R., et al. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.118021
Huang, R., Chu, T., Zhu, G., Tao, C., Qu, W., Fang, Y., Gao, J., Fu, X., Ding, Z., Liu, W., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218818
uPAR-directed immunotherapies in solid tumors: current advances and future perspectives
Napolitano, F., & Montuori, N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1961182
Huang, K., Chen, J., Liu, Y., Ding, C., 易采瀅, Ma, W., Wu, S., & Liu, F. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1868137
The p53-PA200 Feedback Loop Modulates Age-Dependent Tumorigenesis
Jiang, C.-Y., Wang, Y.-L., Lv, N., Cai, B., & Jiang, T.-X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198783
Xiao, R., Hong, J. H., Wang, P., Zhong, Y., Ye, Z., Hao, Z., Gao, J., Yu, J., Peng, Y., Chen, S., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218902
Metadata
- Authors
- Wang, C., Vegna, S., Jin, H., Benedict, B., Lieftink, C., Ramirez, C., de Oliveira, R. L., Morris, B., Gadiot, J., Wang, W., du Chatinier, A., Wang, L., Gao, D., Evers, B., Jin, G., Xue, Z., Schepers, A., Jochems, F., Sanchez, A. M., Mainardi, S., te Riele, H., Beijersbergen, R. L., Qin, W., Akkari, L., & Bernards, R.
- Affiliations
- Shanghai Jiao Tong University (CN)
- The Netherlands Cancer Institute (NL)
- Fudan University (CN)
- Corresponding author
- Qin, Wenxin
- Akkari, Leila
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2019-10-02
- Volume
- 574
- Issue
- 7777
- Pages
- 268-272
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6858884
- OpenAlex
- W2977409903
- Cited by
- 427
- References
- 31
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 85 · 2023: 64 · 2022: 66 · 2021: 67 · 2020: 63
- FWCI
- 33.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- hepatocellular carcinoma, liver cancer, senescence, senolysis, TP53 mutation, sertraline, mTOR signaling, apoptosis, drug combination therapy, kinome screen, antidepressant repurposing
- MeSH terms
- Animals, Disease Models, Animal, Female, Liver Neoplasms, Male, Mice, Inbred BALB C, Mutation, Signal Transduction, Tumor Suppressor Protein p53, Cellular Senescence, Apoptosis, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Sertraline, Cell Line, Tumor, Mice, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
